AptarGroup Inc. outlined its position in drug delivery, dosing and protection technologies during Bank of America’s 2026 Injectable Drug Packaging Virtual Field Trip. The company reported 2025 annual revenue of $3.8 billion and 2025 adjusted EBITDA of $815 million, with the Pharma segment representing 46% of total revenue and 69% of total adjusted EBITDA. Aptar Pharma reported FY 2025 revenue of $1.7 billion, reported net sales growth of 6%, and an adjusted EBITDA margin of 35.0%. The presentation highlighted Aptar’s portfolio across proprietary drug delivery systems, injectable solutions and components, and active material science solutions, as well as its regulatory and manufacturing capabilities, including cleanroom standards and reliability performance cited for emergency medicine applications. Aptar also discussed its pipeline exposure across therapeutic areas, including respiratory, biologics and small-molecule injectables, systemic nasal drug delivery, ophthalmology, vaccines and dermatology. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AptarGroup Inc. published the original content used to generate this news brief on March 02, 2026, and is solely responsible for the information contained therein.